Abstract

Most of patients with head and neck cancers (HNC) need curative radiotherapy either as radical treatment or in the postoperative adjuvant setting. Accurate target definition is paramount to ensure a good outcome of radiotherapy. Pretreatment Computed Tomography (CT) is regularly performed for radiation therapy planning, which both guides dose calculation and aids accurately contouring the tumor volume. Nevertheless, when using CT, the low resolution of soft- tissue and the dental artifacts may render the primary tumor identification difficult. The interobserver inconsistency on the definition of the radiation target volume is additionally a generally perceived issue. With the increase of the frequency of HNC treatment by Intensity-modulated radiotherapy (IMRT), the accurate target volume delineation performed by using Fluorodeoxy D-glucose positron emission tomography combined to CT (FDG-PET/CT) had become even more significant. Nevertheless, the ideal technique for precisely deciding the exact margins and form of the biologic tumor volume (BTV) remains challenging. FDG-PET/CT can define BTVs either for escalation of dose or alternative treatment strategies. Debatable issues still exist on the role of FDG PET/CT during radiotherapy treatment. Moreover, some new PET tracers, other than FDG, have been investigated for imaging specific biologic tumor characteristics in HNC. The purpose of this narrative review is to discuss the use of FDG-PET/CT for BTV definition before and during delivery of radiotherapy for HNC with attention to PET tracers other than FDG.

Keywords: FDG-PET/CT · Biologic target volume · Head and neck cancer · Radiotherapy planning

References

  1. 1.Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Can�cer J. Clin. 61(2): 69-90; 2011.
  2. 2.McMullen K.P. et al. Circulating tumor cells Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer 75 Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439 in head and neck cancer: A review. World Journal of Otorhinolaryngology-Head and Neck Surgery 2: 109 –116; 2016. ment planning, response assessment, and adaptive therapy in head and neck cancer. Radiographics 33: 1909-1929; 2013.
  3. 3.Plaxton N.A. et al. Characteristics and Limitations of FDG PET/CT for Imaging of Squamous Cell Carcinoma of the Head and Neck: A Comprehensive Review of Anatomy, Metastatic Pathways, and Image Findings. AJR :W519–W531; 2015.
  4. 4.ICRU Report 62, Prescribing, Recording and Reporting Photon Beam Therapy, (supplement to ICRU Report 50), 1999.
  5. 5.Peters LJ, O’Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J. Clin. Oncol. 28 (18):2996–3001; 2010.
  6. 6.Danny R. et al. Overview of Advances in Head and Neck Cancer. Journal of Clinical Oncology 33(29) : 3225-3226; 2015.
  7. 7.Njeh CF. Tumor delineation: the weakest link in the search for accuracy in radiotherapy. J. Med. Phys. 33(4):136–140; 2008.
  8. 8.Chen A.M., Farwell D.G., Luu Q., et al. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 80(5):1423–1429; 2011.
  9. 9.Schoenfeld G.O., Amdur R.J., Morris C.G., et al. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 71(2):377–385; 2008.
  10. 10.Bhatnagar P., Subesinghe M., Patel C., et al. Functional imaging for radiation treat76
  11. 11.Cooper J.S., Mukherji S.K., Toledano A.Y., et al. An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). Int. J. Radiat. Oncol. Biol. Phys. 67(4): 972–975; 2007.
  12. 12.Helsen N, Roothans D, Van Den Heuvel B, Van den Wyngaert T, Van den Weyngaert D, Carp L, et al. FFDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy. PLoS ONE12(8): e0182350. https://doi. org/10.1371/journal.pone.0182350; 2017. doi:10.1371/journal.pone.0182350
  13. 13.Troost EG, Bussink J, Hoffmann AL, et al. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J. Nucl. Med. 51(6):866–874; 2010.
  14. 14.Devic S. Towards Biological Target Volumes Definition for Radiotherapy Treatment Planning: Quo Vadis PET/CT? J. Nucl. Med. Radiat. Ther. 4 (3): 5-10; 2013.
  15. 15.Devic S. et al. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes. Br J Radiol. 2016 Jun;89(1062):20150388. Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439
  16. 16.Nishioka T., Shiga T., Shirato H., et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 53, 1051–1057; 2002.
  17. 17.Heron D. E., Andrade R. S., Flickinger J., et al. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int. J. Radiat. Oncol. Biol. Phys. 60: 1419–1424; 2004.
  18. 18.Riegel A. C., Berson A. M., Destian S., et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int. J. Radiat. Oncol. Biol. Phys. 65: 726–732; 2006.
  19. 19.Ciernik, I. F., Dizendorf, E., Baumert, B. G., et al. Radiation treatment plan�ning with an integrated positron emission and computer tomography (PET/ CT): a feasibility study. Int. J. Radiat. Oncol. Biol. Phys. 57: 853–863; 2003.
  20. 20.Paulino A. C., Koshy M., Howell R., et al. Comparison of CT- and FDG-PET defined gross tumor volume in intensity-modulated radiotherapy for headand-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.61:1385–1392; 2005.
  21. 21.Geets X., Lee J.A., Bol A., et al. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur. J. Nucl. Med. Mol. Imaging 34(9):1427–1438; 2007a.
  22. 22.Van Dalen J.A., Hoffmann A. L., Dicken V., et al. A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl. Med. Commun. 28: 485–493; 2007.
  23. 23.Daisne J.F., Duprez T., Weynand B., et al. Tumor volume in pharyngolaryn�geal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233(1):93–100; 2004.
  24. 24.Schinagl DA, Vogel WV, Hoffmann AL, et al. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomographybased target volume definition in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 69(4):1282–1289; 2007.
  25. 25.Moule R. N., Kayani I., Moinuddin S. A., et al. The potential advan� tages of (18)FDG PET/CTbased target volume delineation in radiotherapy planning of head and neck cancer. Radiother. Oncol. 97: 189–193; 2010.
  26. 26.Schinagl D.A., Span P.N., Van den Hoogen F.J., et al. Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer. Eur. J. Nucl. Med. Mol. Imaging 40: 1828-1835; 2013.
  27. 27.Perez-Romasant L.A., Bellon-Guardia M., Torres-Donaire J., et al. Tumor volume delineation in head and neck cancer with 18-F DG/PET : adaptive thresholding method applied to primary tumors and metastatic lymph nodes. Clin. Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer 77 Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439 Transl. Oncol. 15 (4): 283-293; 2013.
  28. 28.Thiagarajan A, Caria N, Schöder H, et al. Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination. Int. J. Radiat. Oncol. Biol. Phys. 2012;83(1):220–227; 2012.
  29. 29.Guardia M.E., Romasanta L.P., Vicente A.M., et al. Utility of PET-CT on radiotherapy planning of head and neck cancer. Rev. ESp. Med. Nucl. 29 (4): 157-164; 2010.
  30. 30.Caldas-Magalhaes J., Kasperts N., Kooij N., et al. Validation of imaging with patho�logy in laryngeal cancer: accuracy of the registration methodology. Int. J. Radiat. Oncol. Biol. Phys. 82(2):e289–e298; 2012.
  31. 31.Chatterjee S., Frew J., Mott J., et al. Variation in radiotherapy target volume definition, dose to organ at risk and clinical target volumes using anatomic (CT) versus combined anatomic and molecular imaging (PET-CT): IMRT delivered using a tomotherapy Hi Art machine: final results of Vortigern study. Clin. Oncol. 24 (10): 173-179; 2012.
  32. 32.Wang D, Schultz CJ, Jursinic PA, et al. Initial experience of FDG-PET/ CT guided IMRT of head-and-neck carcinoma. Int. J. Radiat. Oncol. Bio.l Phys. 65(1):143–151; 2006.
  33. 33.Arslan S., Abakay C.D., Sen F.M et al. Role of PET/CT in treatment planning for Head and neck Cancer Patients Undergoing Definitive Radiotherapy. Asian Pac. J. Cancer Prev. 15: 10899-10903; 2014. 78
  34. 34.Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18FFDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J. Nucl. Med. 46: 1342–1348; 2005.
  35. 35.Greco C., Nehmeh S., Shoder H., et al. Comparison of different methods of FDG-PET target volume delineation in the radiotherapy of head and neck cancer. Int. J. Radiat. Oncol. Biol Phys. 69: S422–S422; 2007.
  36. 36.Kolarova I., Vanasek J., Kandral V., et al. PET/CT siginificance for plan� ning radiotherapy of head and neck cancer. Neoplasma 59: 536-540; 2012.
  37. 37.Grégoire V., Johannes A. Langendijk, and Sandra Nuyts. Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol 33:3277–3284; 2015.
  38. 38.Vernon M.R., Maheshwari M., Schultz C.J., et al. Clinical outcomes of pa� tients receiving integrated PET/ CTguided radiotherapy for head and neck carcinoma. Int. J. Radiat. Oncol. Biol. Phys.70 (3): 678–684; 2008.
  39. 39.Madani I., Duprez F., Boterberg, T., et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother. Oncol. 101: 351–355; 2011.
  40. 40.Rothschild S, Studer G, Seifert B, et al. PET/CT staging followed by intensitymodulated radiotherapy (IMRT) improves treatment outcome of locally advanced Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439 pharyngeal carcinoma: a matched-pair comparison. Radiat. Oncol. 2:22; 2007.
  41. 41.Rasmussen J.H. et al. Phase I trial of 18 F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. Radiother�apy and Oncology 120: 76–80; 2016.
  42. 42.Duprez F, De Neve W, De Gersem W, et al. Adaptive dose painting by numbers for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 80(4):1045–1055; 2011.
  43. 43.Madani I., Duthoy W., Derie C., et al. Positron emission tomography-guided,focaldose escalation using intensitymodulated radiotherapy for head and neck cancer.Int. J. Radiat. Oncol. Biol. Phys. 68, 126–135; 2007.
  44. 44.Corry J., Peters L.J., Rischin D. Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol. 11(3):287–291; 2010. method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. Radiother. Oncol. 95(2):209–217; 2010.
  45. 45.Donaldson S.B., Betts G., Bonington S.C., et al. Perfusion estimated with rapid dynamic contrast-enhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study. Int. J. Radiat. Oncol. Biol. Phys. 81(4):1176–1183; 2011.
  46. 46.Hentschel M., Appold, S., Schreiber A., et al. Early FDG PET at 10 or 20 Gyunderchemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur. J. Nucl. Med. Mol. Imaging 38: 1203–1211; 2011.
  47. 47.Castaldi P., Leccisotti L., Bucciche F., et al. Role of 18F-FDG PET-CT in head and neck squamous cell carcinoma. ActaOtorhinolaryngologica Italia 33:1-8; 2013.
  48. 48.Bittner M.I. et al. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. ACTA ONCOLOGICA 55 (11); 1299–1304; 2016
  49. 49.Geets X., Tomsej M., Lee J.A., et al. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother. Oncol. 85(1):105–115; 2007b
  50. 50.Lin Z., Mechalakos J., Nehmeh S., et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys.70 (4):1219–1228; 2008.
  51. 51.Castadot P, Geets X, Lee JA, et al. As� sessment by a deformable registration
  52. 52.Moule RN, Kayani I, Prior T, et al. Adap�tive 18fluoro-2-deoxyglucose positron Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer 79 Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439 emission tomography/ computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer. Clin. Oncol. 23(5): 364–371; 2011
  53. 53.Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother. Oncol. 77(1):18–24; 2005.
  54. 54.Hall E.J., Giaccia A.J. Oxygen effect and reoxygenation. In: Hall EJ, Giaccia AJ, eds. Radiobiology for the radiologist. Philadelphia, Pa: Lippincott Williams & Wilkins, 85–105; 2006
  55. 55.Eschmann S. M., Paulsen F., Reimold M., et al. Prognostic impact of hypoxia imaging with 18Fmisonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.J. Nucl. Med. 46: 253–260; 2005.
  56. 56.Rischin D., Hicks R. J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomographydetected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-tasman radiation oncology group study 98.02. J. Clin. Oncol. 24, 2098–2104; 2006.
  57. 57.Zimny M., Gagel B., Di Martino E., et al. FDG—a marker of tumor hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastat80 ic head and neck cancer. Eur. J Nucl. Med. Mol. Imaging 33(12):1426–1431; 2006.
  58. 58.Thorwarth D., Eschmann S. M., et al. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head and neck cancer. B.M.C. Cancer 5:152. doi:10.1186/1471-2407-5–152; 2005. doi:10.1186/1471-2407-5–152
  59. 59.Thorwarth, D., Eschmann, S. M., Paulsen, et al. Hypoxia dose painting by numbers: a planning study. Int. J. Radiat. Oncol. Biol. Phys. 68, 291–300; 2007.
  60. 60.Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F- 18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother .Oncol.101(3):369–375; 2011.
  61. 61.Lee N.Y., Mechalakos J. G., Nehmeh S., et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomographyguided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int. J. Radiat. Oncol. Biol. Phys. 70: 2–13; 2008.
  62. 62.Nehmeh S.A., Lee N.Y., Schröder H., et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.Int. J. Radiat. Oncol. Biol. Phys. 70: 235–242; 2008
  63. 63.Linda et al. Comparison of [18F]-FMISO, Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439 [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia – a simulation study. Acta Oncologica 54: 1370–1377; 2015.
  64. 64.Piert M., Machulla H.J., Picchio M., et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J. Nucl. Med. 46(1):106–113; 2005
  65. 65.Grönroos T., Eskola O., Lehtiö K., et al. Pharmacokinetics of [18F] FETNIM: a potential marker for PET. J. Nucl. Med. 42(9):1397–1404; 2001.
  66. 66.Bollineni V.R., Koole M.J., Pruim J., et al. Dynamics of tumor hypoxia assessed by 18F-FAZa PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother. Oncol. 133(2): 198-203; 2014.
  67. 67.Bourgeois, M., Rajerison, H., Guerard, F., et al. Contribution of [64Cu]-ATSM PET in molecular imaging of tumor hypoxia compared to classical [18F]MISO – a selected review. Nucl. Med. Rev. Cent. East Eur. 14: 90–95; 2011
  68. 68.Lewis J.S., McCarthy D.W., McCarthy T.J., et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J. Nucl. Med. 40: 177–183; 1999.
  69. 69.Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensitymodulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 49: 1171–1182; 2001.
  70. 70.Grassi I., Nanni C., Cicoria G., et al. Usefulness of 64 Cu-ATSM in head and neck cancer: a preliminary propspective study. Clin. Nucl. Med. 39: 59-63; 2014
  71. 71.Thorwarth D. Radiotherapy treatment planning based on functional PET/CT imaging data. Nuclear Medicine Review 15:C43-C47; 2012.
  72. 72.Weber W.A. Monitoring tumor response to therapy with 18F-FLT PET. J. Nucl. Med. 51(6):841–844; 2010.
  73. 73.Bussink, J., Van Herpen, C. M., Kaanders, J. H., et al. PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol. 11: 661–669; 2010.
  74. 74.Lodge et al. Repeatability of 18FFLT PET in a Multicenter Study of Patients with High-Grade Glioma. J Nucl Med 58:393–398; 2017.
  75. 75.Rasey J.S., Grierson J.R., Wiens L.W., et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med. 43(9):1210–1217; 2002.
  76. 76.Troost E.G., Schinagl D.A., Bussink J, et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J.Nucl. Med. 51: 66-76; 2010.
  77. 77.Menda Y., Boles Ponto L.L., Dornfeld K.J., et al. Kinetic analysis of 3´-deoxy-3´-(18) F-fluorothymidine ((18)F-FLT) in head Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer 81 Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439 and neck cancer patients before and early after initiation of chemoradiation therapy. J. Nucl. Med. 50(7):1028–1035; 2009. diotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J. Nucl. Med. 51: 528–534; 2010.
  78. 78.de Langen A.J., Klabbers B., Lubberink M., et al. Reproducibility of quantitative 18F-3´-deoxy- 3´-fluorothymidine measurements using positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 36(3):389–395; 2009.
  79. 79.Linecker A., Kermer C., Sulzbacher I., et al. Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 47(2):80–85; 2008.
  80. 80.Troost E.G., Vogel W.V., Merkx M.A., et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J. Nucl. Med. 48(5):726–735; 2007
  81. 81.Shields A. F., Grierson J. R., Dohmen B. M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4: 1334–1336.; 1998.
  82. 82.Arens A.I., Troost E.G., Hoeben B.A., et al. Semiautomatic methods for segmentation of the proliferative tumor volume on sequential FLT PER/CT images in head and neck carcinoma and their relation to clinical outcome. Eur. J. Nucl. Med. Mol. Imaging 41: 915-924; 2014
  83. 83.Yue J., Chen L., Cabrera A.R., et al. Measuring tumor cell prolifera�tion with 18F-FLT PET during ra82 Use of FDG-PET/CT for Biological Target Volume Definition in Head and Neck Cancer
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access